Form D · Biotechnology
Trevi Therapeutics, Inc.
New Haven, CT · CIK 0001563880
Offering snapshot reported Apr 18, 2022 · SEC filing
- Reported sold
- $55M Offering amount: $55M
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 11, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 18, 2022 | Initial | $54,999,998 | No comparison | 12 | SEC filing |
| Oct 21, 2021 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Oct 20, 2021 | Initial | $11,819,891 | No comparison | 1 | SEC filing |
| Sep 5, 2018 | Amendment | $51,906,460 | $10,758,000vs Jul 24, 2017 | 18 | SEC filing |
| Jul 24, 2017 | Initial | $41,148,460 | No comparison | 17 | SEC filing |
| Dec 18, 2012 | Initial | $6,564,102 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.3M
- Finders' fees
- $0
- Form D file number
- 021-442332
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Stifel, Nicolaus & Company, Incorporated | 793 | |
| Needham & Company, LLC | 16360 | |
| Oppenheimer & Co. Inc. | 249 | |
| Aegis Capital Corp. | 15007 |
Source: Form D, filed Apr 18, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mette Kirstine Agger | Director |
| James Cassella | Director |
| Dominick Colangelo | Director |
| Lisa Delfini | Executive |
| Cayce Denton | Director |
| William Forbes | Executive |
| Jennifer L. Good | Director, Executive |
| Michael Heffernan | Director |
| Ed Mathers | Director |
| Edward Mathers | Director |
| David Meeker | Director |
| Annie Mitsak | Director |
| Eran Nadav | Director |
| Thomas Sciascia | Executive |
| Chris Seiter | Executive |
| Joseph Sorrentino | Executive |
| Otello Stampacchia | Director |
| Anne Van Lent | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
195 Church Street 14 Th Floor
New Haven, CT, 06510
New Haven, CT, 06510